成人型黄斑部卵黄样变性的玻璃体腔内雷珠单抗注射治疗。

Primary intravitreal ranibizumab for adult-onset foveomacular vitelliform dystrophy.

机构信息

Department of Ophthalmology, University Hospital La Fe, Valencia, Spain.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2011 Mar;249(3):455-8. doi: 10.1007/s00417-010-1536-1. Epub 2010 Oct 8.

DOI:10.1007/s00417-010-1536-1

PMID:20931215

Abstract

AIM

To evaluate the efficacy of intravitreal injections of ranibizumab in adult-onset foveomacular vitelliform dystrophy (AOFVD).

METHODS

Six female patients were misdiagnosed in the office as occult choroidal neovascularization due to AMD, and scheduled for 3-monthly intravitreal injections of ranibizumab. One month after the third injection, all patients underwent further examinations consisting of visual acuity, optical coherence tomography, Indocyanine Green angiography, electrophysiological tests (electroretinogram and electrooculogram), and an exhaustive familial history of macular diseases. Cases were followed-up every 6 weeks since the formal diagnose of AOFVD was evidenced.

RESULTS

The mean BCVA improved from 0.36 ± 0.1 at baseline to 0.56 ± 0.1 (p = 0.038). No significant change was evidence in the SD-OCT thickness analysis. Metamorphopsia disappeared completely in all cases after the first injection. No familial history was evidenced.

CONCLUSIONS

Ranibizumab intravitreal injections are effective in the short-term BCVA improvement in patients with AOFVD.

摘要

目的

评估玻璃体内注射雷珠单抗治疗成年型黄斑部卵黄样变性（AOFVD）的疗效。

方法

6 名女性患者因 AMD 于诊室被误诊为隐匿性脉络膜新生血管，被安排每 3 个月行玻璃体内注射雷珠单抗。在第 3 次注射后 1 个月，所有患者均接受了进一步的检查，包括视力、光学相干断层扫描、吲哚青绿血管造影、眼电图和视网膜电图检查，以及详尽的黄斑疾病家族史。自确诊 AOFVD 后，每 6 周对患者进行随访。